MedTrace Logo

Automated Screen for Fetal Aneuploidy

NCT03635359 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2018-08-17

No results posted yet for this study

Summary

The purpose of this study is to develop and evaluate a blood test and automated microfluidic test platform for the prenatal screening of fetal aneuploidy.

Conditions

  • Trisomy 21 and Other Fetal Aneuploidy

Interventions

DIAGNOSTIC_TEST

blood test

analysis of cell-free DNA in maternal plasma

Sponsors & Collaborators

  • Brugmann University Hospital

    collaborator OTHER

  • University of British Columbia

    collaborator OTHER

  • Royal Prince Alfred Hospital, Sydney, Australia

    collaborator OTHER

  • Hospital Universitario Virgen de la Arrixaca

    collaborator OTHER

  • Hospital CUF Descobertas, Lisbon, Portugal

    collaborator UNKNOWN

  • University College London Hospitals

    collaborator OTHER

  • BioCeryx

    lead INDUSTRY

Principal Investigators

  • Thomas J Musci, MD · BioCeryx

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-15
Primary Completion
2019-03-31
Completion
2019-06-30

Countries

  • Australia
  • Belgium
  • Canada
  • Portugal
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03635359 on ClinicalTrials.gov